RG
PROF

Redmile Group’s Profound Medical PROF Stock Holding History

Redmile Group’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-787,346
Closed -$11.5M – 76
2021
Q3 		$11.5M Hold
787,346
– – 0.2% 62
2021
Q2 		$12.9M Sell
787,346
-58,328
-7% -$1.09M 0.19% 73
2021
Q1 		$17M Buy
845,674
+20,477
+2% +$491K 0.24% 72
2020
Q4 		$17M Buy
825,197
+197
+0% +$3.62K 0.21% 66
2020
Q3 		$14.6M Buy
825,000
+425,000
+106% +$6.75M 0.27% 61
2020
Q2 		$6.78M Hold
400,000
– – 0.13% 70
2020
Q1 		$3.9M Buy
+400,000
New +$5.19M 0.11% 61

Other funds holding PROF

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Redmile Group's PROF Position: Q4 2021 in Review

Redmile Group sold out of Profound Medical (PROF) in Q4 2021, closing a stake of 787,346 shares — an estimated $11.5M sold.

Redmile Group first reported a position in PROF in Q1 2020 and held it in 7 quarters. The position peaked at $17M in Q1 2021. 46 funds tracked by Wall St. Rank hold PROF as of Q4 2021.

  • Redmile Group reported no remaining Profound Medical position as of Q4 2021 after selling out during the quarter.
  • Redmile Group sold 787,346 Profound Medical shares in Q4 2021, an estimated $11.5M.
  • Redmile Group first reported a position in Profound Medical in Q1 2020 and held it in 7 quarters.
  • Redmile Group's Profound Medical position peaked at $17M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Profound Medical as of Q4 2021.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.